February 28, 2025 07:00 AM EST
Peer Review

Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

William Pao, a long­time R&D leader at Roche who briefly held the chief de­vel­op­ment of­fi­cer post at Pfiz­er

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

At long last, No­var­tis’ ra­dio­phar­ma drug Plu­vic­to gets an ex­pand­ed la­bel

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

A service from the Financial Times